Recent Updates
Recently added Catalysts

BMS-986235

Phase 1

Mediators of Inflammation | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: Mar 31, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment122

FDA Designations

No designations recorded

Clinical trial landscape

BMS-986235 · 1 trial · 1 indication

Phase 1 1
NCT03335553A Study of Experimental Medication BMS-986235 in Healthy SubjectsMediators of Inflammation
COMPLETED122 Analytics
PHASE1COMPLETED
A Study of Experimental Medication BMS-986235 in Healthy Subjects
Mediators of Inflammation
NCT03335553122
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of serious adverse events (SAE)
Approximately 30 days
Number of deaths
Approximately 30 days
Number of adverse events (AE) leading to study discontinuation
Approximately 30 days
Number of patients with clinically significant changes in ECG parameters, as defined by the investigator
Approximately 30 days
Number of patients with potentially clinically significant changes in vital signs
Approximately 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ascending dose (SAD): BMS-986235 or PlaceboEXPERIMENTALBMS-986235 or Placebo oral dose
Multiple ascending dose (MAD): BMS-986235 or PlaceboEXPERIMENTALBMS-986235 or Placebo oral dose

Interventions

NameTypeDescription
BMS-986235DRUGSpecified dose on specified days
PlaceboOTHERSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Patients must be normal healthy volunteers as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations * Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive Exclu...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about BMS-986235

What is BMS-986235 used for?

BMS-986235 is an investigational small molecule being studied for conditions related to mediators of inflammation. It is currently in Phase 1 clinical development, with a completed trial in healthy subjects. The drug is not yet approved and remains under investigation by Bristol-Myers Squibb.

What does BMS-986235 target?

The specific molecular target of BMS-986235 has not been disclosed in available information. The drug is being studied for its effects on mediators of inflammation, but its precise mechanism of action is not publicly detailed.

Who makes BMS-986235?

BMS-986235 is developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research on this investigational small molecule.

What phase is BMS-986235 in?

BMS-986235 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval and is still being evaluated for safety and tolerability in clinical studies.

What clinical trials is BMS-986235 in?

BMS-986235 has one completed clinical trial, NCT03335553, titled "A Study of Experimental Medication BMS-986235 in Healthy Subjects." This Phase 1 study enrolled 122 participants in the United States and was a randomized, double-blind, controlled trial.

Is BMS-986235 the same as any other drug?

No alternative names for BMS-986235 have been reported. The drug is identified solely by its development code BMS-986235, and no other names or aliases are associated with it in available information.